MedTrace Logo

Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

NCT00590694 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2012-04-12

No results posted yet for this study

Summary

Patients with neovascular Age-related macular degeneration (AMD) and the particular feature of pigment epithelial detachments (PEDs) were not studied in the Phase III trials for ranibizumab (Lucentis). The PrONTO study was the first ranibizumab study to enroll such patients but only treated with ranibizumab until fluid within the layers of the retina was absent, not until the entire PED was absent. This study hypothesizes that there may be a difference in benefit between patients treated until just the retinal edema is gone and those in which the retinal edema and PED are both gone.

Conditions

  • Age-related Macular Degeneration
  • Pigment Epithelial Detachment
  • Neovascular Macular Degeneration
  • Wet Macular Degeneration

Interventions

DRUG

ranibizumab

0.5mg injection monthly according to protocol for one year

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Pacific Eye Associates

    lead OTHER

Principal Investigators

  • Anne Fung, MD · Pacific Eye Associates / California Pacific Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00590694 on ClinicalTrials.gov